


<https://meetings.asco.org/am/virtual-program>

Cancer Center Members indicated in



[\(LBA2\) A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy](#)

Cancer Center members indicated in BOLD

Copenhagen Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; CHA Bundang Medical Center, CHA University, Bundang, South Korea; Massachusetts General Hospital, Cambridge, MA; Massachusetts General Hospital, Boston, MA; Symphogen A/S, Ballerup, Denmark; Bioinformatics, Guardant Health, Redwood City, CA; Guardant Health, Redwood City, CA; Nadler Pharma Associates, LLC, Randolph, NJ; Formerly Eli Lilly and Company, Bridgewater, NJ; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain



[\(1002\) TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response \(DDR\) pathway genes \(Olaparib Expanded\).](#)

Oral Abstract Session: Breast Cancer—Metastatic

Authors: Nadine M. Tung, Mark E. Robson, Steffen Venz, Cesar Augusto Santa-Maria, Paul Kelly Marcom, Rita Nanda, Payal D Shah, Tarah Jean Ballinger, Eddy Shih-Hsin Yang, Michelle E. Melisko, Adam Brufsky, Shaveta Vinayak, Michelle Demeo, Colby Jenkins, Susan M. Domchek, Gerburg M. Wulf, Ian E. Krop, Antonio C. Wolff, Eric P. Winer, Judy Ellen Garber, Translational Breast Cancer Research Consortium; Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Brookline, MA; Northwestern University Feinberg School of Med

Cancer Center members indicated in BOLD

Cancer Center members indicated in BOLD

Breast Cancer—Local/Regional/Adjuvant – Local-Regional Therapy

Authors: Michael Kharouta, Nicholas Damico, Eleanor Elizabeth Harris

; University

Cancer Center members indicated in BOLD

[\(4643\) A pilot study to determine the feasibility of a customized low glycemic load diet in patients with stage I-III colorectal cancer.](#)

Cancer Center members indicated in BOLD

Koyfman, Deborah Chute, **Wade Thorstad**, Justin A. Bishop, Farhoud Faraji, James Lewis Jr., ; Case Western Reserve University, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH; Cleveland Clinic, Cleveland, OH; **WashU** in St. Louis, St. Louis, MO; UT Southwestern Medical Center, Dallas, TX; University of California, San Diego, San Diego, CA; Vanderbilt University Medical Center, Nashville, TN; Case Western Reserve University, Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH

(6566) Combination of tumor multinucleation and spatial arrangement of tumor-

Cancer Center members indicated in BOLD

Center and Case Western Reserve University, Cleveland, OH; Division of Hematology, Oncology and

Cancer Center members indicated in BOLD

[\(TPS8068\) Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced-stage Hodgkin lymphoma \(Trial in Progress\).](#)

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia – Hodgkin Lymphoma
Authors: Judah D. Friedman, Hun Ju Lee, Linda Ho, Ian Flinn; University Hospitals Seidman Cancer Center, Cleveland, OH; The University of Texas MD Anderson Cancer Center, Houston, TX; Seattle Genetics, Inc., Bothell, WA; Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN

[\(TPS9080\) Phase I study of AMG 757, a half-life extended bispecific T-cell engager \(HLE BiTE immune therapy\) targeting DLL3, in patients with small cell lung cancer \(SCLC\).](#)

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Small Cell Lung Cancer

Authors: Taofeek Kunle Owonikoko, Hossein Borghaei, Stéphane Champiat, Luis G. Paz-Ares, Ramaswamy Govindan, Michael J. Boyer, Melissa Lynne Johnson, Hibiki Udagawa, Horst-Dieter Hummel, Ravi Salgia, Fiona Helen Blackhall, Rene J. Boosman, Wei-Chu Victoria Lai, , Everett E. Vokes, Christine L. Hann, Anne C. Chiang, Marichu Endraca, Neelesh Soman, Marie-Anne Damiette Smit; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Fox Chase Cancer Center, Philadelphia, PA; Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif, France; Hospital Universitario 12 de Octubre, H120H120-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense & Ciberonc, Madrid, Spain; Divisions of Hematology and Oncology, Washington University Medical School, St. Louis, MO; Chris O'Brien Lifecare, Camperdown, NSW, Australia; Lung Cancer Research, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA; Department of Medical Oncology, The Christie NHS Foundation Trust, Division of Cancer Sciences, Manchester, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center, New York, NY; Division of Hematology and Oncology, Department of Medicine, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH; University of Chicago Medicine and Biological Sciences, Chicago, IL;

Cancer Center members indicated in BOLD

Cancer Center members indicated in BOLD

[\(e17513\) Prostate cancer outcomes by ESRD status](#)

Genitourinary Cancer—Prostate, Testicular, and Penile—Biomarkers/Epidemiology/Outcomes

Authors:

Cancer Center members indicated in BOLD

[\(e24052\) Improve a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-hispanic white breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics](#)

Symptoms and Survivorship—Health Promotion

Authors: , Paul F. Hergenroeder, Kris Austin, Beth Bennett, Stephen Cerne, Jean Petkac, Kathryn H. Schmitz, Monica Webb-Hooper, Leonard Wimbley, Sarah Coccia, Caitlin Nagy, ; Case Western Reserve University School of Medicine, Cleveland, OH; MetroHealth Medical Center, Cleveland, OH; The Gathering Place, Beachwood, OH; Cleveland Clinic, Cleveland, OH; University Hospitals of Cleveland, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University of Pennsylvania, Philadelphia, PA; Case Western Reserve Univ, Cleveland, OH

[\(e24176\) Decision aids for localized prostate cancer: Initial outcomes from NCI Community Oncology Research Program Alliance Research Base Cancer Care Delivery Resear](#)